Trial Profile

A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination with dose in Patients with Recurrent or Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Regorafenib (Primary)
Indications Adenocarcinoma; Astrocytoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Glioblastoma; Head and neck cancer; Oesophageal cancer; Oropharyngeal cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer
Focus Therapeutic Use
Sponsors Bayer

Most Recent Events

23 Jul 2024 Status changed from active, no longer recruiting to completed.
18 Apr 2024 This Trial has been completed in Belgium, according to Eudra record
28 Feb 2024 Planned End Date changed from 16 Aug 2024 to 27 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com